<DOC>
	<DOCNO>NCT00428584</DOCNO>
	<brief_summary>To evaluate tolerability new formulation rebif Betaseron subject relapsing-remitting multiple sclerosis ( RRMS ) compare mean change injection site pain score pre-injection 30 minute post therapy administration .</brief_summary>
	<brief_title>RNF Betaseron® Tolerability Study</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Interferon beta-1b</mesh_term>
	<criteria>1 . Subject diagnosis RRMS accord McDonald criterion Poser 2 . Subject 18 60 year old inclusive 3 . Subject willing follow study procedures 4 . Subject give write informed consent 5 . Female subject must neither pregnant breastfeeding must lack childbearing potential , define either : Being postmenopausal surgically sterile , Using hormonal contraceptive , intrauterine device , diaphragm spermicide , condom spermicide , duration study . 1 . Subject Clinically Isolated Syndrome ( CIS ) , Primary Progressive MS , Secondary Progressive MS without superimposed relapse . 2 . Subject prior interferon beta therapy ( either beta1b beta1a ) prior study Day 1 . 3 . Subject receive approved disease modify therapy MS ( glatiramer acetate ) cytokine anticytokine therapy within 3 month prior Study Day 1 . 4 . Subject receive immunomodulatory immunosuppressive therapy ( include limit cyclophosphamide , cyclosporin , methotrexate , azathioprine , linomide , mitoxantrone , teriflunomide , natalizumab , laquinimod , Campath cladribine ) within 12 month prior Study Day 1 . 5 . Subject prior use Cladribine previously receive total lymphoid irradiation . 6 . Subject know allergy natural recombinant interferon component formulation excipient ( ) Rebif® Betaseron® : Mannitol , Poloxamer 188 , Methionine , Benzyl alcohol Albumin ( human ) . 7 . Use injectable medication regular basis week prior screening period screen treatment period . Receiving single injection treatment prophylaxis condition unrelated subject 's multiple sclerosis subject 's Rebif® Betaseron® therapy ( e.g . receive influenza pneumococcus vaccination ) acceptable . 8 . History chronic pain syndrome . 9 . Subject disease apart MS could better explain subject sign symptom . 10 . Subject complete transverse myelitis bilateral optic neuritis . 11 . Subjects use investigational drug experimental procedure within 12 week prior visit 1 . 12 . Subject inadequate liver function , define total bilirubin , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) alkaline phosphatase &gt; 2.5 time upper limit normal value . 13 . Subject inadequate bone marrow reserve , define white blood cell count le 0.5 x low limit normal . 14 . Subject suffers current autoimmune disease ( RRMS ) . 15 . Subject suffers major medical psychiatric illness opinion investigator create undue risk subject could affect compliance study protocol 16 . Subject pregnant attempt conceive 17 . Visual physical impairment precludes completion diary questionnaires . 18 . Subject receive oral systemic corticosteroid ACTH within 30 day visit 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>